Clinical Trials Logo

Clinical Trial Summary

Community-acquired pneumonia (CAP) is a heterogeneous disease causing great morbidity, mortality and health care burden globally. Typing methods for discriminating different clinical conditions of the same disease are essential to a better management of CAP. Traditional typing systems based separately on clinical manifestations (such as PSI and CURB-65), pathogens(bacterial types, virulence, drug resistance, etc) or host immune state (immunocompetent, immunocompromised or immunodeficiency). Thus, they are barely able to represent the real disease status nor to precisely predict the mortality.

As the development of multi-omic technologies, the relatedness of different phenotypes at a molecular level have revolutionized our ability to differentiate among patients. Our study is aimed at establishing a novel molecular typing method of CAP. Multi-omic (including genomics, transcriptomes, and metabolisms) data obtained from enrolled CAP patients and isolated pathogens would be integrated analyzed and interpreted. Tthe investigators believe that an appropriate molecular typing method would lead to revolutionary changes in current arrangements of CAP.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03093220
Study type Observational
Source Peking University People's Hospital
Contact Yali Zheng, Dr
Phone 15011451515
Email drylzheng@gmail.com
Status Recruiting
Phase N/A
Start date March 2017
Completion date December 2018

See also
  Status Clinical Trial Phase
Completed NCT01734486 - Growth Response in Girls With Turner Syndrome Phase 4
Completed NCT01529944 - Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658 Phase 3
Completed NCT01518036 - Use of Somatropin in Turner Syndrome Phase 3
Completed NCT00025870 - Studies of Children With Metabolic and Other Genetic Disorders
Completed NCT01563926 - Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Phase 3
Active, not recruiting NCT01851447 - Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
Completed NCT01435629 - A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin N/A
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Terminated NCT01135537 - Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants Phase 2
Completed NCT00705172 - Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
Completed NCT01518062 - Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Phase 4
Recruiting NCT02769949 - Pediatric Patients With Metabolic or Other Genetic Disorders
Terminated NCT00358657 - Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders Phase 2
Completed NCT01604161 - Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome N/A
Completed NCT01516229 - Special Survey for Long Term Application N/A
Enrolling by invitation NCT04681781 - SLC13A5 Deficiency Natural History Study - Remote Only
Completed NCT01529840 - Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome Phase 3
Completed NCT01710696 - Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome Phase 3
Completed NCT01401244 - Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers Phase 1
Recruiting NCT05737602 - Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease N/A